Pacer Advisors
IBRX icon

Pacer Advisors’s ImmunityBio IBRX Stock Holding History

Pacer Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,478
Closed -$15.7K – 2616
2024
Q2 		$15.7K Sell
2,478
-3,619
-59% -$23.9K ﹤0.01% 3476
2024
Q1 		$32.7K Buy
+6,097
New +$27.6K ﹤0.01% 3336
2021
Q2 		– Sell
-1,618
Closed -$38K – 1468
2021
Q1 		$38K Buy
+1,618
New +$41.9K ﹤0.01% 1468

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pacer Advisors's IBRX Position: Q3 2024 in Review

Pacer Advisors sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 2,478 shares — an estimated $15.7K sold.

Pacer Advisors first reported a position in IBRX in Q1 2021 and held it in 3 quarters. The position peaked at $38K in Q1 2021. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • Pacer Advisors reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 2,478 ImmunityBio shares in Q3 2024, an estimated $15.7K.
  • Pacer Advisors first reported a position in ImmunityBio in Q1 2021 and held it in 3 quarters.
  • Pacer Advisors's ImmunityBio position peaked at $38K in Q1 2021.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.